(Q37969115)

26 August 2017

The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review (English)

1 reference

focal segmental glomerulosclerosis

26 August 2017

1 reference

1 reference

1 reference

Carlos E Araya

1

1 reference

PMC publication ID

3235904

26 August 2017

Vikas R Dharnidharka

series ordinal

2

1 reference

26 August 2017

24 November 2011

1 reference

Journal of transplantation

26 August 2017

1 reference

26 August 2017

2011

1 reference

26 August 2017

374213

1 reference

Creative Commons Attribution 3.0 Unported

26 August 2017

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

Creative Commons Attribution 3.0 Unported

0 references

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Rituximab in refractory nephrotic syndrome.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Rituximab for post-transplant recurrences of FSGS.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235904

Rituximab for plasma exchange-dependent recurrent focal segmental glomerulosclerosis after renal transplantation

1 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1155%2F2011%2F374213

Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome

21 January 2018

1 reference

12 December 2020

Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment

1 reference

12 December 2020

Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation?

1 reference

12 December 2020

Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab

1 reference

12 December 2020

Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis

1 reference

12 December 2020

Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports

1 reference

12 December 2020

A glomerular permeability factor produced by human T cell hybridomas

1 reference

12 December 2020

Post-transplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy

1 reference

12 December 2020

Rituximab therapy in early recurrent focal segmental sclerosis after renal transplantation

1 reference

12 December 2020

Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases

1 reference

12 December 2020

Increased nitric oxide production by T- and B-cells in idiopathic nephrotic syndrome

1 reference

12 December 2020

Nephrotic syndrome and rituximab: facts and perspectives

1 reference

12 December 2020

Use of Rituximab in Focal Glomerulosclerosis Relapses After Renal Transplantation

1 reference

12 December 2020

Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis

1 reference

12 December 2020

Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation

1 reference

12 December 2020

Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation - case report

1 reference

12 December 2020

CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes

1 reference

12 December 2020

Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome

1 reference

12 December 2020

Identifiers

DOI

10.1155/2011/374213

1 reference

26 August 2017

1 reference

PMC publication ID

3235904

26 August 2017

PubMed publication ID

22174985

1 reference

PMC publication ID

3235904